MANKIND PHARMA Financial Statement Analysis
|
||
The Revenues of MANKIND PHARMA have increased by 12.44% YoY .
The Earnings Per Share (EPS) of MANKIND PHARMA has decreased by -10.56 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
MANKIND PHARMA Last 5 Annual Financial Results
[BOM: 543904|NSE : MANKIND]
Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
---|---|---|---|---|---|
Revenues | ₹8,749 Cr | ₹7,782 Cr | ₹6,214 Cr | ₹5,872 Cr | ₹4,980 Cr |
Expenses | ₹6,848 Cr | ₹5,791 Cr | ₹4,565 Cr | ₹4,427 Cr | ₹4,055 Cr |
Operating Profit (Excl OI) | ₹1,902 Cr | ₹1,991 Cr | ₹1,649 Cr | ₹1,445 Cr | ₹925 Cr |
Other Income | ₹129 Cr | ₹196 Cr | ₹171 Cr | ₹104 Cr | ₹53 Cr |
Interest | ₹46 Cr | ₹60 Cr | ₹21 Cr | ₹23 Cr | ₹44 Cr |
Depreciation | ₹326 Cr | ₹167 Cr | ₹119 Cr | ₹99 Cr | ₹69 Cr |
Profit Before Tax | ₹1,671 Cr | ₹1,975 Cr | ₹1,692 Cr | ₹1,438 Cr | ₹875 Cr |
Profit After Tax | ₹1,310 Cr | ₹1,453 Cr | ₹1,293 Cr | ₹1,056 Cr | ₹610 Cr |
Consolidated Net Profit | ₹1,282 Cr | ₹1,433 Cr | ₹1,265 Cr | ₹1,030 Cr | ₹579 Cr |
Earnings Per Share (Rs) | ₹32.00 | ₹35.78 | ₹31.59 | ₹25.72 | ₹14.44 |
PAT Margin (%) | 14.38 | 18.00 | 20.00 | 17.31 | 12.26 |
ROE(%) | 19.27 | 26.72 | 31.51 | 33.48 | 21.41 |
ROCE(%) | 23.49 | 33.96 | 39.97 | 43.57 | 28.80 |
Total Debt/Equity(x) | 0.02 | 0.14 | 0.05 | 0.04 | 0.10 |
Key Financials |
||
Market Cap | : | ₹ 83,865.6 Cr |
Revenue (TTM) | : | ₹ 10,334.8 Cr |
Net Profit(TTM) | : | ₹ 1,926.6 Cr |
EPS (TTM) | : | ₹ 48.1 |
P/E (TTM) | : | 43.5 |
Industry Peers & Returns | 1W | 1M | 1Y |
MANKIND PHARMA | -6.1% | -11.9% | 54.1% |
SUN PHARMACEUTICAL INDUSTRIES | -0.9% | 0.9% | 62.6% |
CIPLA | 3.5% | 4.2% | 51.8% |
DR REDDYS LABORATORIES | -1% | -2.4% | 28.4% |
ZYDUS LIFESCIENCES | 12.2% | 18% | 103.8% |
DIVIS LABORATORIES | 0.8% | 5.6% | 19.3% |
TORRENT PHARMACEUTICALS | 2.9% | 6.2% | 66.2% |
LUPIN | 1.5% | 4.2% | 109.2% |
AUROBINDO PHARMA | 3.1% | 7.9% | 81.3% |
MANKIND PHARMA Revenues
[BOM: 543904|NSE : MANKIND]
Y-o-Y | 12.44 % |
5 Yr CAGR | 15.13 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2023 | ₹8,749 Cr | 12.44 | |
Mar2022 | ₹7,782 Cr | 25.22 | |
Mar2021 | ₹6,214 Cr | 5.83 | |
Mar2020 | ₹5,872 Cr | 17.91 | |
Mar2019 | ₹4,980 Cr | - |
MANKIND PHARMA Operating Profit
[BOM: 543904|NSE : MANKIND]
Y-o-Y | -4.45 % |
5 Yr CAGR | 19.75 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2023 | ₹1,902 Cr | -4.45 | |
Mar2022 | ₹1,991 Cr | 20.70 | |
Mar2021 | ₹1,649 Cr | 14.15 | |
Mar2020 | ₹1,445 Cr | 56.18 | |
Mar2019 | ₹925 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | -15.01 % |
5 Yr CAGR | 4.02 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2023 | 21.74% | -15.01 | |
Mar2022 | 25.58% | -3.62 | |
Mar2021 | 26.54% | 7.89 | |
Mar2020 | 24.6% | 32.47 | |
Mar2019 | 18.57% | - |
MANKIND PHARMA Profit After Tax
[BOM: 543904|NSE : MANKIND]
Y-o-Y | -10.58 % |
5 Yr CAGR | 22.01 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2023 | ₹1,282 Cr | -10.58 | |
Mar2022 | ₹1,433 Cr | 13.28 | |
Mar2021 | ₹1,265 Cr | 22.81 | |
Mar2020 | ₹1,030 Cr | 78.11 | |
Mar2019 | ₹579 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | -20.11 % |
5 Yr CAGR | 4.07 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2023 | 14.38 % | -20.11 | |
Mar2022 | 18 % | -10.00 | |
Mar2021 | 20 % | 15.54 | |
Mar2020 | 17.31 % | 41.19 | |
Mar2019 | 12.26 % | - |
MANKIND PHARMA Earnings Per Share (EPS)
[BOM: 543904|NSE : MANKIND]
Y-o-Y | -10.56 % |
5 Yr CAGR | 22.01 % |
Years | EPS | % Change | |
---|---|---|---|
Mar2023 | ₹32 | -10.56 | |
Mar2022 | ₹36 | 13.26 | |
Mar2021 | ₹32 | 22.82 | |
Mar2020 | ₹26 | 78.12 | |
Mar2019 | ₹14 | - |
MANKIND PHARMA Return on Capital Employed (ROCE)
[BOM: 543904|NSE : MANKIND]
Y-o-Y | -30.83 % |
5 Yr CAGR | -4.97 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2023 | 23.49% | -30.83 | |
Mar2022 | 33.96% | -15.04 | |
Mar2021 | 39.97% | -8.26 | |
Mar2020 | 43.57% | 51.28 | |
Mar2019 | 28.8% | - |
MANKIND PHARMA Share Price vs Sensex
Current Share Price | : | ₹2,093.5 |
Current MarketCap | : | ₹ 83,865.6 Cr |
Updated EOD on | : | May 17,2024 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
MANKIND PHARMA | -6.1% |
-11.9% |
54.1% |
SENSEX | 1.7% |
0.7% |
19.2% |
MANKIND PHARMA related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE ALLCAP | 3% | 3% | 37% |
S&P BSE 500 | 2.9% | 2.8% | 35.1% |
S&P BSE 250 LARGEMIDCAP | 2.7% | 2.6% | 33.2% |
S&P BSE LARGE MIDCAP | 2.6% | 2.5% | 33.1% |
S&P BSE 200 | 2.6% | 2.5% | 32.7% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY MID SMALL400 | 4.5% | 5.1% | 60.1% |
NIFTY MIDCAP150 | 4.5% | 5.3% | 57.8% |
NIFTY FREE MIDCAP 100 | 4.2% | 4.7% | 58.9% |
NIFTY500 MULTICAP 50:25:25 | 3.5% | 3.6% | 44.5% |
NIFTY LARGE MIDCAP 250 | 3.4% | 3.7% | 43% |
You may also like the below Video Courses
FAQ about MANKIND PHARMA Financials
How the annual revenues of MANKIND PHARMA have changed ?
The Revenues of MANKIND PHARMA have increased by 12.44% YoY .
How the Earnings per Share (EPS) of MANKIND PHARMA have changed?
The Earnings Per Share (EPS) of MANKIND PHARMA has decreased by -10.56 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs